Contrasting Envoy Medical (NASDAQ:COCH) & Inogen (NASDAQ:INGN)

Inogen (NASDAQ:INGN) and Envoy Medical (NASDAQ:COCH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Inogen and Envoy Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1	2	1	0	2.00
Envoy Medical	0	0	2	0	3.00

Inogen presently has a consensus price target of $7.50, indicating a potential upside of 6.38%. Envoy Medical has a consensus price target of $6.00, indicating a potential upside of 20.48%. Given Envoy Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Envoy Medical is more favorable than Inogen.

Profitability

This table compares Inogen and Envoy Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inogen	-32.46%	-38.98%	-27.03%
Envoy Medical	N/A	N/A	-100.39%

Risk & Volatility

Inogen has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500.

Earnings & Valuation

This table compares Inogen and Envoy Medical’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$315.66 million	0.53	-$102.45 million	($4.41)	-1.60
Envoy Medical	$320,000.00	305.03	-$29.91 million	N/A	N/A

Envoy Medical has lower revenue, but higher earnings than Inogen.

Insider & Institutional Ownership

89.9% of Inogen shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 0.6% of Inogen shares are owned by company insiders. Comparatively, 0.7% of Envoy Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Envoy Medical beats Inogen on 9 of the 12 factors compared between the two stocks.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

About Envoy Medical

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.